IDORSIA LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.22 CHF | -5.61% |
|
+2.78% | +5.01% |
| May. 07 | Idorsia Secures Bondholders' Approval for Amendment to Terms of Outstanding Convertible Bonds | MT |
| May. 02 | Idorsia Boosts Consent Fee Offer to 2024 Convertible Bond | MT |
ETFs positioned on Idorsia Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 746 M€ | -.--% | - | |
| 0.00% | 10 M€ | -3.35% | - | |
| 0.00% | 34 M€ | +3.87% | - | |
| 0.00% | 7 M€ | +0.11% | - | |
| 0.00% | 146 M€ | -2.01% | - | |
| 0.00% | 25 M€ | -2.62% | - | |
| 0.00% | 1 M€ | 0.00% | - | |
| 0.00% | 29 M€ | -1.43% | - |
Idorsia Ltd is a Switzerland-based biopharmaceutical company, which specializes in the discovery and development of small molecules, to meet significant unmet medical needs. The Company will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The Company's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
Calendar
2024-05-21
- Q1 2024 Earnings Release - Q4 2023
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
8
Last Close Price
2.22
CHF
Average target price
1.724
CHF
Spread / Average Target
-22.35%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +5.01% | 438M | |
| +9.42% | 115B | |
| +11.84% | 106B | |
| -14.15% | 21.84B | |
| -1.05% | 21.96B | |
| -5.29% | 19.21B | |
| -38.29% | 17.71B | |
| -4.16% | 18.08B | |
| +7.99% | 14.32B | |
| +36.24% | 12.42B |
- Stock Market
- Equities
- IDIA Stock
- Funds and ETFs Idorsia Ltd
